EHA 2016 Conference Review - Focus on Multiple Myeloma

 In this Review:

DRD vs. RD in relapsed/refractory MM: POLLUX
Bortezomib/dexamethasone ±daratumumab in relapsed/refractory MM: CASTOR
PD-1 blockade enhances elotuzumab efficacy in murine model
Weekly KCyd followed by weekly carfilzomib in elderly, newly diagnosed MM
OS in MM treated with lenalidomide after high-dose melphalan and autologous SCT
Del17p MM outcomes
Venetoclax monotherapy for relapsed/ refractory MM
Elotuzumab monotherapy in high-risk smouldering MM
Echocardiographic assessment of ENDEAVOUR participants receiving Cd or Bd for relapsed MM

Please login below to download this issue (PDF)

Subscribe